
Julian Carretero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1086291/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 2013, 3, 1355-1363. | 7.7 | 1,073 |
| 2 | Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2014, 26, 909-922. | 7.7 | 376 |
| 3 | Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biology and Medicine, 2002, 33, 387-398. | 1.3 | 338 |
| 4 | Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. Cancer Cell, 2010, 17, 547-559. | 7.7 | 215 |
| 5 | Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by <i>EML4-ALK</i> Fusion Oncogene. Cancer Research, 2010, 70, 9827-9836. | 0.4 | 181 |
| 6 | Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radical Biology and Medicine, 1999, 26, 410-418. | 1.3 | 180 |
| 7 | Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 6183-6192. | 3.2 | 179 |
| 8 | Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. Journal of Thoracic Oncology, 2017, 12, 1268-1279. | 0.5 | 152 |
| 9 | Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 4973-4985. | 3.2 | 141 |
| 10 | Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625. | 2.6 | 130 |
| 11 | HIF2α cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 2160-2170. | 3.9 | 129 |
| 12 | Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology, 2004, 39, 711-720. | 3.6 | 127 |
| 13 | Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in <i>LKB1</i> -Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879. | 7.7 | 127 |
| 14 | Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8699-8704. | 3.3 | 114 |
| 15 | Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene, 2004, 23, 4037-4040. | 2.6 | 111 |
| 16 | Intratumoral Heterogeneity in <i>EGFR</i> -Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research, 2015, 75, 4372-4383. | 0.4 | 108 |
| 17 | Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021. | 7.7 | 108 |
| 18 | Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors, Genes Chromosomes and Cancer, 2004, 41, 170-177. | 1.5 | 103 |

JULIAN CARRETERO

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. Clinical and Experimental Metastasis, 1999, 17, 567-574. | 1.7 | 99 |
| 20 | Acceleration of Glutathione Efflux and Inhibition of Î ³ -Glutamyltranspeptidase Sensitize Metastatic B16 Melanoma Cells to Endothelium-induced Cytotoxicity. Journal of Biological Chemistry, 2005, 280, 6950-6959. | 1.6 | 82 |
| 21 | γ-Clutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology, 2002, 35, 74-81. | 3.6 | 81 |
| 22 | Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Molecular Cancer Therapeutics, 2008, 7, 3330-3342. | 1.9 | 81 |
| 23 | β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations. Cancer Research, 2014, 74, 5891-5902. | 0.4 | 76 |
| 24 | Novel Transcriptional Targets of the SRY-HMG Box Transcription Factor SOX4 Link Its Expression to the Development of Small Cell Lung Cancer. Cancer Research, 2012, 72, 176-186. | 0.4 | 73 |
| 25 | D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490. | 2.7 | 70 |
| 26 | Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease. Clinical Cancer Research, 2007, 13, 2658-2666. | 3.2 | 68 |
| 27 | Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213. | 3.2 | 66 |
| 28 | Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213. | 3.2 | 66 |
| 29 | Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro. PLoS ONE, 2020, 15, e0228909. | 1.1 | 66 |
| 30 | PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data. Genome Medicine, 2018, 10, 41. | 3.6 | 63 |
| 31 | Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene, 2004, 23, 5084-5091. | 2.6 | 61 |
| 32 | Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. Human Molecular Genetics, 2005, 14, 973-982. | 1.4 | 55 |
| 33 | Tumoricidal Activity of Endothelial Cells. Journal of Biological Chemistry, 2001, 276, 25775-25782. | 1.6 | 47 |
| 34 | Tumor Cytotoxicity by Endothelial Cells. Journal of Biological Chemistry, 2003, 278, 13888-13897. | 1.6 | 44 |
| 35 | <i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Research, 2015, 75, 1287-1297. | 0.4 | 44 |
| 36 | CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Research, 2019, 79, 4439-4452. | 0.4 | 44 |

JULIAN CARRETERO

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Down-regulation of Glutathione and Bcl-2 Synthesis in Mouse B16 Melanoma Cells Avoids Their Survival during Interaction with the Vascular Endothelium. Journal of Biological Chemistry, 2003, 278, 39591-39599. | 1.6 | 42 |
| 38 | Bcl-2 and Mn-SOD Antisense Oligodeoxynucleotides and a Glutamine-enriched Diet Facilitate Elimination of Highly Resistant B16 Melanoma Cells by Tumor Necrosis Factor-α and Chemotherapy. Journal of Biological Chemistry, 2006, 281, 69-79. | 1.6 | 40 |
| 39 | Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Radical Biology and Medicine, 2000, 29, 913-923. | 1.3 | 38 |
| 40 | Glutamine potentiates TNF-α-induced tumor cytotoxicity. Free Radical Biology and Medicine, 2001, 31, 642-650. | 1.3 | 36 |
| 41 | De novo lipogenesis represents a therapeutic target in mutant Kras nonâ€small cell lung cancer. FASEB Journal, 2018, 32, 7018-7027. | 0.2 | 33 |
| 42 | LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics. Analytical Chemistry, 2019, 91, 836-845. | 3.2 | 33 |
| 43 | Temporal Molecular and Biological Assessment of an Erlotinib-Resistant Lung Adenocarcinoma Model Reveals Markers of Tumor Progression and Treatment Response. Cancer Research, 2012, 72, 5921-5933. | 0.4 | 31 |
| 44 | Expression inactivation of SMARCA4 by microRNAs in lung tumors. Human Molecular Genetics, 2015, 24, 1400-1409. | 1.4 | 26 |
| 45 | Abstract B290: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors , 2013, , . | | 26 |
| 46 | Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer. PLoS ONE, 2013, 8, e80885. | 1.1 | 23 |
| 47 | Possible Mechanisms for Tumour Cell Sensitivity to TNF-a and Potential Therapeutic Applications. Current Pharmaceutical Biotechnology, 2001, 2, 119-130. | 0.9 | 17 |
| 48 | Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels. Nitric Oxide - Biology and Chemistry, 2008, 19, 107-114. | 1.2 | 15 |
| 49 | Endothelin-1–Mediated Drug Resistance in <i>EGFR</i> -Mutant Non-Small Cell Lung Carcinoma. Cancer Research, 2020, 80, 4224-4232. | 0.4 | 12 |
| 50 | Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. Cancers, 2020, 12, 3712. | 1.7 | 6 |
| 51 | Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. Cancer Cell, 2015, 27, 149. | 7.7 | 3 |
| 52 | A role for the 2-oxoglutarate carrier in glutathione transport into hepatocyte mitochondria?. Hepatology, 2004, 39, 570-571. | 3.6 | 2 |
| 53 | A Very Rare Variant in SREBF2, a Possible Cause of Hypercholesterolemia and Increased Glycemic Levels. Biomedicines, 2022, 10, 1178. | 1.4 | 2 |
| 54 | ETS-1 Regulates Twist-1 Expression In Non-Small Cell Lung Cancer (NSCLC) Progression And Metastasis. , 2011, , . | | 1 |

JULIAN CARRETERO

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Srebf2 Locus Overexpression Reduces Body Weight, Total Cholesterol and Glucose Levels in Mice Fed with Two Different Diets. Nutrients, 2020, 12, 3130. | 1.7 | 1 |
| 56 | Epigenetics and precision medicine in lung cancer. , 2022, , 109-145. | | 1 |
| 57 | Increased Ets-1 Positively Correlates With Twist1 Expression In Mouse Non-small Cell Lung Cancer (NSCLC) Progression And Metastases. , 2010, , . | | 0 |
| 58 | Abstract A292: Salinomycin, an anti-cancer stem cell antibiotic, overcomes acquired resistance to BRAF inhibitors inBRAF-mutant human melanoma cell lines , 2013, , . | | 0 |
| 59 | Abstract 968: β-catenin plays an important role in lung tumor development induced by EGFR mutations. , 2014, , . | | 0 |
| 60 | Abstract 3940: Inactivation of the PARD3 gene is a recurrent event in lung squamous cell carcinomas and affects STAT3 activity and tumor invasiveness. , 2015, , . | | 0 |
| 61 | Abstract 753: Genomic alterations of autophagy genes disrupts autophagic flux in human lung adenocarcinomas. , 2015, , . | | 0 |
| 62 | Abstract 766: Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M. , 2015, , . | | 0 |
| 63 | Abstract 4479: Unveiling the relationship between the SWI/SNF chromatin remodeling complex and noncoding RNAs. , 2016, , . | | 0 |
| 64 | Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients Journal of Clinical Oncology, 2020, 38, e15042-e15042. | 0.8 | 0 |